Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Etigilimab

Monoclonal antibody · Antagonist of TIGIT · developed by Mereo BioPharma

Phase 2 Most advanced trial
MREO Developer
1 Registered trials

What is Etigilimab?

Etigilimab is a monoclonal antibody that binds the immune checkpoint receptor TIGIT on T cells and other immune cells, blocking its interaction with CD112 and CD155. This releases CD226 costimulatory signaling in NK and CD8-positive T cells. It is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
TIGIT, CD112 (nectin-2) (NECTIN2) (binding partner it blocks), CD155 (poliovirus receptor) (PVR) (binding partner it blocks), CD226 (DNAM-1) (CD226) (secondary target)
Mechanism
Antagonist of TIGIT
Pathways
CD226-mediated signaling, T-cell activation and proliferation
Therapy area
Oncology
Developer
Mereo BioPharma (MREO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FC1ZF28VIT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05715216 Phase 2 Ovarian Cancer Active not recruiting MREO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Other drugs acting on TIGIT

More from Mereo BioPharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.

Follow MREO, the company behind Etigilimab

See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MREO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.